Free Trial

Arbutus Biopharma (ABUS) Competitors

Arbutus Biopharma logo
$3.18 +0.09 (+2.91%)
Closing price 07/1/2025 04:00 PM Eastern
Extended Trading
$3.25 +0.07 (+2.17%)
As of 09:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ABUS vs. OGN, MIRM, AMRX, IBRX, XENE, BHC, GMTX, APLS, ARWR, and TWST

Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), ImmunityBio (IBRX), Xenon Pharmaceuticals (XENE), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.

Arbutus Biopharma vs. Its Competitors

Organon & Co. (NYSE:OGN) and Arbutus Biopharma (NASDAQ:ABUS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Organon & Co. presently has a consensus price target of $18.00, indicating a potential upside of 79.64%. Arbutus Biopharma has a consensus price target of $5.50, indicating a potential upside of 72.96%. Given Organon & Co.'s higher probable upside, analysts clearly believe Organon & Co. is more favorable than Arbutus Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organon & Co.
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.50
Arbutus Biopharma
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Organon & Co. has higher revenue and earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organon & Co.$6.40B0.41$864M$2.883.48
Arbutus Biopharma$6.17M98.71-$69.92M-$0.41-7.76

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 1.4% of Organon & Co. shares are held by company insiders. Comparatively, 20.3% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Organon & Co. has a net margin of 11.92% compared to Arbutus Biopharma's net margin of -1,196.64%. Organon & Co.'s return on equity of 227.43% beat Arbutus Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Organon & Co.11.92% 227.43% 7.34%
Arbutus Biopharma -1,196.64%-75.51%-55.81%

Organon & Co. has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

In the previous week, Organon & Co. had 42 more articles in the media than Arbutus Biopharma. MarketBeat recorded 44 mentions for Organon & Co. and 2 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.37 beat Organon & Co.'s score of 0.10 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organon & Co.
3 Very Positive mention(s)
4 Positive mention(s)
32 Neutral mention(s)
4 Negative mention(s)
1 Very Negative mention(s)
Neutral
Arbutus Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Organon & Co. beats Arbutus Biopharma on 11 of the 17 factors compared between the two stocks.

Get Arbutus Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABUS vs. The Competition

MetricArbutus BiopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$591.82M$2.85B$5.48B$8.94B
Dividend YieldN/A2.69%5.38%4.12%
P/E Ratio-7.7621.1726.2219.74
Price / Sales98.71262.85394.92109.12
Price / CashN/A41.8936.4957.06
Price / Book6.247.237.915.37
Net Income-$69.92M-$55.05M$3.15B$248.34M
7 Day Performance-4.79%-0.60%0.75%1.67%
1 Month Performance-5.36%3.77%3.46%4.56%
1 Year Performance1.60%2.20%34.60%18.42%

Arbutus Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABUS
Arbutus Biopharma
1.9372 of 5 stars
$3.18
+2.9%
$5.50
+73.0%
+1.9%$591.82M$6.17M-7.7690
OGN
Organon & Co.
4.8976 of 5 stars
$9.82
+0.7%
$18.00
+83.3%
-50.6%$2.55B$6.40B3.414,000
MIRM
Mirum Pharmaceuticals
3.6492 of 5 stars
$50.28
-0.1%
$65.50
+30.3%
+41.7%$2.49B$336.89M-31.23140
AMRX
Amneal Pharmaceuticals
3.0716 of 5 stars
$7.91
+1.2%
$11.60
+46.6%
+27.9%$2.48B$2.79B-197.708,100
IBRX
ImmunityBio
2.0603 of 5 stars
$2.76
-3.8%
$12.25
+343.8%
-59.0%$2.44B$14.74M-4.76590
XENE
Xenon Pharmaceuticals
3.1338 of 5 stars
$31.49
-1.7%
$54.82
+74.1%
-14.9%$2.42B$9.43M-9.75210
BHC
Bausch Health Cos
3.2323 of 5 stars
$6.11
-1.1%
$7.42
+21.4%
-4.4%$2.26B$9.73B-55.5520,700
GMTX
Gemini Therapeutics
N/A$51.61
+3.0%
N/A+17.5%$2.24BN/A-51.6130High Trading Volume
APLS
Apellis Pharmaceuticals
4.515 of 5 stars
$17.62
-0.4%
$40.05
+127.3%
-50.8%$2.21B$775.84M-9.84770News Coverage
Analyst Revision
ARWR
Arrowhead Pharmaceuticals
3.9208 of 5 stars
$15.51
+1.2%
$43.71
+181.8%
-38.2%$2.14B$3.55M-11.08400Positive News
TWST
Twist Bioscience
4.3388 of 5 stars
$35.33
+2.0%
$50.40
+42.7%
-24.9%$2.12B$347.68M-10.87990News Coverage

Related Companies and Tools


This page (NASDAQ:ABUS) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners